Login to Your Account



Other News To Note


Friday, May 25, 2012
• Gilead Sciences Inc., of Foster City, Calif., said the European Medicines Agency validated its marketing authorization application (MAA) for cobicistat, submitted on April 26. Cobicistat is Gilead's pharmaco-enhancing agent to increase blood levels of certain commercially available protease inhibitors, including atazanavir (Reyataz, Bristol-Myers Squibb Co.) and darunavir (Prezista, Tibotec Pharmaceuticals), to enable once-daily dosing.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription